In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference.

Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018.

Guests:

Dr. Tina Cascone
Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center in Houston, Texas

Dr. Marina Chiara Garassino
Director, Thoracic Oncology Program and Professor of Medicine
University of Chicago

Dr. Matthew Smeltzer
Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health
University of Memphis

Professor Caicun Zhou
Chief Physician and Director of the Department of Medical Oncology
Tongji University in Shanghai Pulmonary Hospital